Antiviral Drugs - Northern Europe

Northern Europe

The Antiviral Drugs market in Northern Europe is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$0.57bn in 2024.
Furthermore, it is anticipated that the market will exhibit a steady annual growth rate of 1.37% from 2024 to 2029, resulting in a market volume of US$0.61bn by 2029.
In terms of global comparison, United States is predicted to generate the highest revenue in the Antiviral Drugs market.
It is estimated that the revenue United States will amount to US$30,640.00m in 2024.
In Northern Europe, the demand for antiviral drugs is surging due to the region's proactive approach towards public health and preparedness for viral outbreaks.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for antiviral drugs has been on the rise in Northern Europe due to various factors.

Customer preferences: Customers in Northern Europe have shown a preference for antiviral drugs that are effective against a wide range of viruses. They also prefer drugs that have minimal side effects and are easy to administer.

Trends in the market: The market for antiviral drugs in Northern Europe has been growing steadily due to the increasing prevalence of viral infections. The COVID-19 pandemic has also contributed to the growth of the market as there has been a surge in demand for antiviral drugs that can treat the virus. The market has also seen an increase in the development of new antiviral drugs that are more effective and have fewer side effects.

Local special circumstances: Northern Europe is home to a large aging population, which is more susceptible to viral infections. This has contributed to the increasing demand for antiviral drugs in the region. Additionally, the region has a high incidence of influenza, which has led to the development of antiviral drugs that are effective against the virus.

Underlying macroeconomic factors: The healthcare sector in Northern Europe is well developed and has a high level of funding. This has contributed to the growth of the antiviral drugs market in the region. The region also has a high level of healthcare awareness among its population, which has led to an increase in demand for antiviral drugs. Additionally, the region has a strong pharmaceutical industry, which has led to the development of new antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.